1 Full title (<250 chars): Respiratory virus concentrations in human excretions that

2 contribute to wastewater: A systematic review

3 Short title (<100 chars): A systematic review of respiratory virus concentrations in

- 4 excretions found in wastewater
- 5

6 Sarah A. Lowry^a, Marlene K. Wolfe^b, Alexandria B. Boehm^a

7

8 a. Department of Civil and Environmental Engineering, Stanford University, 473 Via

- 9 Ortega, Stanford, California 94305, United States
- 10 b. Gangarosa Department of Environmental Health, Rollins School of Public Health,

11 Emory University, 1518 Clifton Rd., Atlanta, Georgia 30322, United States

12

13 Abstract

14 Concentrations of nucleic acids from a range of respiratory viruses including human

15 influenza A and B, respiratory syncytial virus (RSV), metapneumovirus, parainfluenza

16 virus, rhinovirus, and seasonal coronaviruses in wastewater solids collected from

- 17 wastewater treatment plants correlate to clinical data on disease occurrence in the
- 18 community contributing to the wastewater. Viral nucleic acids enter wastewater from
- 19 various excretions including stool, urine, mucus, sputum, and saliva deposited in toilets
- 20 or other drains in buildings. In order to relate the measured concentrations in
- 21 wastewater at a treatment plant to actual number of infections in a community,
- 22 concentrations of the viral nucleic acids in these human excretions are needed as inputs
- to a mass balance model. In this study, we carried out a systematic review and meta-
- 24 analysis to characterize the concentrations and presence of influenza A and B,
- 25 respiratory syncytial virus (RSV), metapneumovirus, parainfluenza virus, rhinovirus, and
- seasonal coronaviruses in stool, urine, mucus, sputum, and saliva. The systematic
- 27 review protocol can be accessed at <u>https://doi.org/10.17605/OSF.IO/ESVYC</u>. We
- 28 identified 220 data sets from 50 unique articles that met inclusion criteria and reported
- 29 information on viral concentrations and presence in these excretions. Data were
- 30 unevenly distributed across virus type (with the most available for influenza) and
- 31 excretion type (with the most available for respiratory excretions). The majority of data
- 32 sets only reported the presence or absence of the virus in an excretion in a cross-
- 33 sectional study design. There is a need for more concentration data, including
- 34 longitudinal data, across all respiratory virus and excretion types. Such data would allow
- 35 quantitatively linking virus wastewater concentrations to numbers of infected individuals.
- 36

37

38 Introduction

- 39 Respiratory viruses are responsible for millions of infections around the world each
- 40 year. In 2019, acute lower respiratory infections were the leading cause of death
- 41 globally in children under five years old (1). Several key viruses are responsible for the
- 42 majority of respiratory viral infections: human rhinovirus, human parainfluenza viruses 1,
- 43 2, 3, and 4, influenza viruses A and B, respiratory syncytial virus (RSV),
- 44 metapneumovirus, human coronaviruses 229E, HKU1, OC43, and NL63, adenovirus,
- 45 human bocavirus, and non-rhinovirus enterovirus (2). For example, human rhinoviruses
- 46 are the most significant causes of the common cold, influenza A and B viruses cause
- 47 annual epidemics, and RSV and metapneumovirus are estimated to have infected
- 48 almost all children by the time they reach the age of five (3). Additionally, the recent
- 49 SARS-CoV-2 pandemic has underscored the public health threat that respiratory
- 50 viruses pose.
- 51

52 The detection of SARS-CoV-2 RNA in wastewater has led to the rapid growth of

- 53 wastewater-based epidemiology (WBE) as a tool to aid public health officials in
- 54 identifying population-level trends throughout the SARS-CoV-2 pandemic. More
- recently, wastewater surveillance of RSV (4) and influenza (5) has been shown to be
- 56 strongly correlated with the clinical incidence of these diseases. Additionally, rhinovirus
- 57 (6), parainfluenza viruses, metapneumovirus, and seasonal coronaviruses 229E, HKU1,
- 58 OC43, and NL63 have all been detected in wastewater where they are correlated to
- 59 clinical measures of disease occurrence (7), indicating that wastewater surveillance of
- 60 respiratory viruses may be a viable tool for public health officials to implement alongside
- 61 conventional surveillance methods.
- 62

63 While WBE is useful in identifying community-level trends in infections, there is a lack of 64 information on how to translate viral nucleic-acid concentrations measured in

- 64 Information on now to translate viral nucleic-acid concentrations measured in 65 wastewater directly to aggregated case numbers. The ability to make this translation
- 65 wastewater directly to aggregated case numbers. The ability to make this translation
- 66 would significantly increase the power of WBE by enabling one to estimate disease
- occurrence directly from wastewater. Many factors and variables influence the potential
 translation from viral nucleic acid quantities in wastewater to the number of cases (5,8),
- but perhaps one of the variables with the most uncertainty is the virus concentration in
- 70 human excretions that contribute to wastewater. These excretions include not only stool
- and urine but also mucus, saliva, and sputum. Thus, the aim of this systematic review is
- to characterize respiratory virus concentrations in excretions that contribute to
- 73 wastewater and identify critical knowledge gaps for further research. Here, we present a
- characterization of respiratory virus concentration and presence across excretion types
- 75 from studies examining subjects with respiratory virus infections.
- 76

77 Methods

78

79 Systematic Review

The systematic review followed PRISMA guidelines (9). This review aimed to gather 80 81 and synthesize the existing literature on shedding patterns and concentrations of respiratory viruses in the various excretions that contribute to wastewater. The 82 83 respiratory viruses included in this review were human rhinovirus, human parainfluenza viruses 1, 2, 3, and 4, influenza viruses A and B, respiratory syncytial virus (RSV), 84 metapneumovirus, and human coronaviruses 229E, HKU1, OC43, and NL63. The 85 86 excretions considered in the review were mucus, saliva, sputum, urine, and stool. The primary goal of the review was to compile concentrations, in units of virus or viral 87 genomes or viral genes per mass or volume of excretion, of respiratory viruses 88 measured in stool, urine, sputum, mucus, and saliva. 89 90

91 The review protocol for this systematic review can be found at

92 https://doi.org/10.17605/OSF.IO/ESVYC (10). Searches were conducted for each

93 respiratory virus between June and August 2022 in the following three databases: Web

of Science (search field = topic), PubMed (search field = title/abstract), and Scopus

95 (search field = title/abstract/keywords). The search string consisted of two fields. The

96 first field was the name of the respiratory virus and any common variations or

abbreviations of that name, and the second field contained the list of excretions of

98 interest. The first field changed for each respiratory virus and is shown in Table 1. The

99 second field remained constant for each respiratory virus and was as follows: (urine OR

feces OR faeces OR fecal OR stool OR sputum OR mucus OR saliva). Once searches
 were conducted, records were uploaded into Covidence, a web-based software platform

102 made for systematic and literature reviews (11). In Covidence, records were

103 deduplicated, screened, and extracted for data analysis. The inclusion criteria were as

follows: each record had to (1) be published in English, (2) be published in a peer-

reviewed journal, (3) contain primary data (i.e. not reviews), (4) contain extractable

106 shedding data, where "shedding data" is defined as measured concentrations or

107 presences of viruses or their genetic material in urine, stool, sputum (including

108 expectorated and induced sputum), mucus (including nasal and nasopharyngeal

aspirates), or saliva; data had to be from direct excretion measurements and not from

areas of the body that generate excretions (e.g. swabs and lavages) and concentrations

111 had to be presented in externally valid units (some measure of virus numbers per

volume or mass of excretion and not per mass or volume of nucleic-acid or nucleic acid

extract, viral transport media, or other media), (5) contain shedding data from humans,

and (6) contain shedding data from subjects infected with the virus of interest or with

respiratory and/or gastrointestinal symptoms and not related to a chronic health

116 condition (i.e. COPD, cystic fibrosis). Inclusion criteria were chosen to ensure only

- 117 credible and original data relevant to the aim of this systematic review were eligible for
- 118 inclusion. First articles were screened using their title and abstract and if deemed to
- potentially fit the inclusion criteria, they were subject to full text review. Articles that fit
- 120 the inclusion criteria passed full text review and were included in the systematic review.
- 121
- 122 Table 1. Search terms for each respiratory virus and the date searched for each
- 123 respiratory virus. Date is in MM/DD/YY format.

Respiratory Virus	Search terms	Date Searched
Rhinovirus	rhinovirus* OR HRV*	06/22/22
Human Parainfluenza Viruses 1, 2, 3, and 4	parainfluenza* OR HPIV* OR PIV	07/13/22
Influenza A and B	"influenza A" OR "influenzavirus A" OR "type A influenza" OR IAV OR "A flu" OR "flu A" OR "influenza B" OR "influenzavirus B" OR "type B influenza" OR IBV OR "B flu" OR "flu B"	07/20/22
Respiratory Syncytial Virus	RSV OR "respiratory syncytial virus" OR "human orthopneumovirus"	07/28/22
Human Metapneumovirus	metapneumovirus* OR "human metapneumovirus" OR hMPV OR HMPV OR MPV	08/25/22
Human Coronaviruses 229E, HKU1, NL64, and OC43 HCoV NL63" OR NL63 OR "human coronavirus OC43" OR HCoV-NL63 OC "HCoV NL63" OR NL63 OR "human coronavirus OC43" OR HCoV-OC43 OC "HCoV OC43" OR OC43 OR "human coronavirus HKU1" OR HCoV-HKU1 OC "HCoV HKU1" OR HKU1		08/29/22

124

125 The following data were extracted from each paper found to fit the inclusion criteria by 126 an independent author. First, we noted whether data were obtained using a cross-127 sectional study design (many individuals sampled each one time), or a longitudinal 128 study design (one or more individuals with samples collected at more than one time 129 point post infection onset); we also noted when in some cases, a cross sectional study 130 incidentally sampled one or more individuals more than once. Second, we noted the 131 virus type and subtype if applicable, virus detection method, and excretion type. Third, 132 we extracted from the publication the concentrations of the virus measured in the

133 excretions as well as any information about the time point in the infection of the

- 134 individual. Fourth, if concentrations were not reported, we noted whether excretions
- 135 were positive for the virus (positivity rates), as well as any information about the time
- 136 point in the infection of the individual. A positivity rate was defined in this review as the
- 137 number of samples that tested positive for the respiratory virus divided by the total
- number of samples tested (i.e. a positivity rate of 10/20 means out of 20 samples taken, 138
- 139 10 tested positive and 10 tested negative for the presence of the virus). In some cases, 140 information about concentrations or positivity rates were provided as only summary
- 141 statistics by authors and in those cases, those were extracted and the type of summary
- 142 statistic was noted. If a study reported shedding data only in a graphical format,
- 143 WebPlotDigitizer (12) was used for data extraction.
- 144
- 145 Meta-analysis
- 146 Data sets from longitudinal and cross sectional studies were reported separately for
- 147 both positivity rates and concentrations. For each data set, the population studied was
- 148 categorized as (1) subjects with confirmed infections of the respiratory virus in question,
- 149 or (2) subjects without confirmed infections but with respiratory and/or gastrointestinal
- 150 symptoms. A confirmed infection was defined as the positive detection of the virus in at
- 151 least one clinical sample out of at least two paired samples (for example, if considering
- 152 positivity rates in stool in a study that examined stool and nasal swabs, confirmed
- 153 infections were individuals with positive stool samples, nasal swabs, or both).
- 154
- 155 Data sets from studies with subjects without confirmed infections but with respiratory and/or gastrointestinal symptoms were used to supplement the primary analysis that 156
- focused on subjects with confirmed infections. These data sets were supplementary 157
- because subjects without confirmed infections but with symptoms may not have been 158
- 159 infected with a viral pathogen rather than infected with a viral pathogen but not shedding
- that pathogen in excretions, and thus were considered separately than data sets of 160
- subjects with confirmed infections. These data sets of subjects without confirmed 161
- infections were used to provide evidence that viral shedding is possible in excretions 162
- 163 that were not examined by data sets of subjects with confirmed infections.
- 164
- 165 Reported concentrations of viruses were represented graphically for comparison among 166 different data sets and types of excretions. Concentrations from cross-sectional studies 167 were graphed separately from concentrations from longitudinal studies. Positivity rates 168 from longitudinal studies were reported individually and separately from positivity rates 169 from cross-sectional studies. Positivity rates from cross-sectional studies for each excretion type were combined across data sets using a weighted average. The 170 171 weighted average was calculated in the statistical computing program R (13) using the following formula: $\frac{\Sigma \text{ positive samples}}{\Sigma \text{ total samples}}$ where the numerator represents the sum of positive 172

samples across relevant data sets and the denominator represents the sum of all

- samples tested across relevant data sets. We tested whether the excretion positivity
- rates were the same within viruses using either a chi-square test for non-sparse data
- 176 (i.e. 20% or less of values in the table were less than 5) or a Fisher's exact test for
- sparse data (i.e. more than 20% of values in the table were less than 5). We completed
- the statistics using RStudio (version 2022.07.1) using R (version 4.1.2) (13), as pre-
- specified in the protocol registration. While some data points were correlated as some
- excretion samples came from the same subject (e.g. when a study collected pairedsamples), we were unable to account for correlation in comparing samples across all
- excretion types. We conducted 6 hypothesis tests and therefore to achieve alpha = 0.05
- in the hypothesis tests, we used a p value of 0.008 (0.05/6) to adjust for multiple
- 184 comparisons (Bonferroni correction). All data used in this paper are available publicly
- 185 through the Stanford Data Repository (<u>https://doi.org/10.25740/vj779wy5347</u>).
- 186

187 **Results**

- 188
- 189 Systematic review results

190 The search process identified a total of 220 data sets from 50 unique articles published

191 in peer-reviewed journals. Figure 1 shows the search process for each respiratory virus.

A data set is defined as concentration or positivity rate data for one virus type (e.g. a

- 193 study reporting both Influenza A and Influenza B data in an excretion would have two
- data sets) in a specific excretion. If an article provided data for multiple excretions, then
- 195 data from each excretion made up a unique data set. Many articles included data on
- 196 multiple respiratory viruses.
- 197
- 198
- 199



200

Figure 1. Modified PRISMA flow diagram showing the results of the systematic review search process.

203

- 204 *Rhinovirus.* We identified 17 papers (14–30) with data on rhinovirus in excretions of
- 205 patients; these papers contained 20 rhinovirus data sets. Of the 20 data sets, one

reported longitudinal positivity rates, three reported concentrations from cross-sectional
 studies, and the remaining 16 data sets reported positivity rates from cross-sectional
 studies that included between three (29) and 312 (26) subjects with confirmed

- 209 infections. Of the 20 data sets, 15 measured the virus using RT-PCR-based methods
- 210 (14,15,17,20–30) while the remaining five used cultivation methods (16,18,19).
- 211

212 The longitudinal data set reported rhinovirus positivity rates in mucus in 26 patients

infected with rhinovirus infections over eight weeks (21). The study indicated 26/26

(100%) detects on Day 0, 13/26 (50%) detects at two weeks follow up, 1/26 (4%)
detects at five weeks follow up, and 0/26 detects at eight weeks follow up.

216

217 Only three data sets reported rhinovirus concentrations in excretions; one data set

218 reports only one datapoint and the remaining two report only summary statistics (Table

219 2). Data sets reported a median concentration of on the order of 10^3 genomes per mg

stool from 11 subjects, 100 TCID₅₀ (median tissue culture infectious dose) per g stool

from one subject, and a geometric mean of on the order of 10 TCID₅₀ per ml saliva from

222 7 subjects. There are too few data to complete a statistics test to compare

- concentrations across excretions, particularly since most of the studies only reportedsummary statistics.
- 225

Excretion Type	Data Format	Concentration	Units	Number of subjects	Publication
Stool	Median (IQR)	4124 (9117)	genomes/mg	11	Bergallo et al. 2019 (14)
Stool	Single sample	100	TCID₅₀/g	1	Cate et al. 1967 (16)
Saliva	Geometric mean	15.85	TCID₅₀/mL	7	Gwaltney et al. 1978 (18)

Table 2. Concentrations of rhinovirus reported in excretions. IQR is interquartile range.

227

The weighted average percentage of positive samples identified in each excretion type

of subjects with confirmed rhinovirus infections is provided in Figure 2, as calculated

from the 16 positivity rate data sets from cross-sectional studies. The highest positivity

rate was found in mucus samples, while the lowest was found in stool. No studies of

subjects with confirmed infection reported measurements of rhinovirus in urine. Fisher's

exact test resulted in a p-value of less than 0.001 rejecting the null hypothesis that

234 positivity rates across excretions are the same.

235

Since no urine data was identified in studies conducted with subjects with confirmed
rhinovirus infections, we looked at data sets in which rhinovirus was tested in excretions
of people with respiratory or gastrointestinal symptoms. None of these data sets
reported on rhinovirus in urine (see Supporting Information Table S1).



241

Figure 2. Weighted Average Percentage of Positive Rhinovirus Detections in Various Excretions of Subjects with Confirmed Rhinovirus Infections. The reported value for n is the total number of samples included in the meta-analysis for each excretion type. The number on top of each bar is the percent of samples positive. No data is reported for urine as no study measured rhinovirus in urine.

- 247
- 248

Parainfluenza Virus. We identified 16 articles (15,19,20,22–34) that reported 32 data
 sets of parainfluenza virus 1, 2, 3, and/or 4 shedding in excretions in patients. These
 data sets all measured positivity rates in subjects with confirmed infections in cross sectional studies that included between one (23–25,28) and 88 (26) subjects. No
 identified data sets reported parainfluenza virus concentrations in any excretion, and
 none reported longitudinal shedding data. None of the data sets measured

- parainfluenza virus in stool or urine. Thirty-one data sets measured parainfluenza virus
 using RT-PCR assays, and one data set used culture methods (19).
- 257

For the 32 data sets, some of them differentiated between the types of parainfluenza

- virus. Seven (7) data sets measured parainfluenza virus 1, six (6) measured
- parainfluenza virus 2, nine (9) measured parainfluenza virus 3, three (3) measured
- 261 parainfluenza virus 4, and seven (7) did not specify a single type of parainfluenza virus.
- See Supporting Information Figure S1 for the weighted average positivity rate by parainfluenza type.
- 264

Positivity rates in mucus, saliva, and sputum are above 60% with the highest positivity rates observed in mucus (Figure 3). Fisher's exact test resulted in a p-value of less than 0.001 rejecting the null hypothesis that positivity rates among excretions are the same.







270

- Figure 3. Weighted Average Percentage of Positive Parainfluenza Virus Detections in Various Excretions from Subjects with Confirmed Infection. The reported value for n is the number of tests included in the metaanalysis for each excretion type. No data is
- reported for stool or urine as no study measured parainfluenza virus in stool or urine.
- 275 The number on top of each bar is the percent of samples positive.
- 276

277 Since no stool or urine data was identified in studies conducted with subjects with

confirmed parainfluenza infections, we examined data sets that tested for parainfluenza

virus in the excretions of people with respiratory or gastrointestinal symptoms. One of
these data sets reported on parainfluenza virus in stool and reported 1/331 stool
samples (0.3%) positive for parainfluenza virus 2, 3, or 4 (the study did not report data
on parainfluenza virus 1) (35). None of the data sets measured parainfluenza virus in

- 283 urine. See Supporting Information Table S2 for additional details of these data sets.
- 284

Influenza. We identified 37 articles (15,19,22–34,36–52,52–56) with data on influenza
in patient excretions; these articles contained 77 influenza data sets. Seventy-six of the
data sets were generated using RT-PCR and the remaining one used culture methods
(19). Eight of the 77 data sets reported longitudinal shedding data (of these 8, two
reported positivity rates (55), and six reported concentrations (44)), 10 reported
concentration data from cross-sectional studies (38,40,41,44), and the remaining 59
reported cross-sectional positivity rate data from between one (24,28,45,46) and 120
(54) aubiests with confirmed influenze infectione.

- 292 (54) subjects with confirmed influenza infections.
- 293

The two longitudinal data sets reporting positivity rates (one for sputum, one for stool) came from a study that provided the number of days after influenza symptom onset that the excretion first tested positive for Influenza A H7N9: a median of 10.5 days (interquartile range 8.25 - 11.75) for sputum, and a median of seven days (interquartile range 7 - 7.75) for stool (55); overall 10/12 subjects were found to contain influenza A in at least one sputum sample and 6/12 subjects were found to contain influenza A in at least one stool sample.

301

The six longitudinal concentration data sets came from a single study (44) that examined the sputum and stool of three patients, two infected with influenza A H3N2 and one with influenza B, over 35 days (Table 3). In these patients, influenza was detected in stool through day 24 but was only detected in sputum through day five or 7. Sputum concentrations ranged from 3.3×10^2 copies/mL to 1.5×10^8 copies/mL, while stool concentrations ranged from 4.7×10^3 copies/g to 1.0×10^5 copies/g over time.

308





310 Figure 4: Concentrations of influenza measured in stool (A) and sputum (B) in three 311 patients (two with Influenza A, as indicated by A (1) and A (2), and one with influenza B) 312 over 35 days, as reported by Hirose et al. (44). A point located at a v-value of 0 313 represents ND (not detected), indicating the virus was not detected. Concentrations

314 were reported in copies/mL for sputum and copies/g for stool.

315

316 Of the 69 cross-sectional data sets, 42 measured influenza A, 21 measured influenza B, 317 and six did not discern between influenza A and B (19,25,29,30,33,47) (either because 318 they did not specify which they measured, they measured both types with the same 319 assay, or they measured both types with separate assays but reported combined 320 results). The breakdown by type A or B is shown in the concentration data in Figure 5 321 and in the positivity rate data in Supplementary Information Figure S2. Some of the 322 cross-sectional data sets additionally specified the influenza A subtype measured: seven measured influenza A H1N1 (39,41,48,50,52,53), 9 measured influenza A H3N2 323 324 (37,41,44), and two measured influenza A H7N9 (56).

325

326 Of the 10 data sets reporting influenza concentrations measured in cross-sectional 327 studies, eight measured the concentration of influenza in stool (reported and calculated medians span 1.6 x 10^4 to 1.3 x 10^5 copies/g stool), and two measured the

- 328
- 329 concentration of influenza in sputum (reported and calculated medians span 2.6 x 10⁶ to
- 330 5.9 x 10⁶ copies/mL sputum) (Figure 5). Samples were acquired from patients at a
- 331 variety of times post symptom onset (38,40,41,44). Concentrations were measured
- 332 using RT-PCR methods. Authors provided summary statistics and point values for 5

datasets (38,41,44), and summary statistics were calculated using data extracted via
WebPlotDigitizer (12) for the remaining 5 datasets (38,40,44).

335



336

337 Figure 5. Concentrations of influenza in stool (A) and sputum (B), where points represent medians and bars indicate interguartile range (IQR) (single points indicate 338 only one datapoint reported from data set by study authors). Data in (A) and (B) comes 339 340 from only cross-sectional studies. Red points represent Influenza A and blue points represent Influenza B. The first author and year is used only to abbreviate the paper 341 342 author list due to lack of space. There are two data sets from the same paper with the same number of subjects (n); these data sets are delineated by adding a (2) after one of 343 344 the data sets. The number of subjects (n) for each data set is provided under the data set name. The papers from which these data sets came include Arena et al. (38). Chan 345 et al. (40), Chan et al. (41), and Hirose et al. (44). The * next to the first author and year 346 indicates datasets that display summary statistics that we calculated. 347 348

Figure 6 shows the weighted average positivity rate data from cross-sectional studies separated by excretion type. Positivity rates of mucus, saliva, and sputum were greater than 80% while positivity rates for urine and stool were 58% and 36%, respectively. A chi-square test resulted in a p-value of less than 0.001, rejecting the null hypothesis that positivity rate is the same across excretions. See Supporting Information Table S3 for data sets of subjects without confirmed influenza infections.



356

Figure 6. Weighted Averages for Percentage of Positive Influenza Virus A or B
Detections in Various Excretions from Subjects with Confirmed Infection. The reported
value for n is the number of samples included in the weighted average for each
excretion type. The number on top of each bar is the percent of samples positive.

362 Respiratory Syncytial Virus (RSV). We identified 20 studies containing 28 data sets 363 with information on the shedding of RSV in excretions of subjects. One data set reported longitudinal positivity rates, one data set reported concentrations of RSV in 364 excretions from a cross-sectional study (specifically in mucus, Table 3), and the 365 remaining 26 reported positivity rate data from cross-sectional studies with between one 366 367 (23) and 323 (26) subjects with confirmed RSV infections. Two data sets measured RSV A, three data sets measured RSV B, and the remaining 23 did not specify a type of 368 369 RSV in their analyses. Twenty-eight of the data sets were generated using RT-PCR and 370 the remaining one used culture methods (19).

371

The longitudinal data set reported the percent of RSV detections in mucus from 38 subjects over 27 days, with RSV detected in 38/38 (100%) of subjects on day 0, 20/38 (53%) of subjects on days 5-13, 9/34 (26%) of subjects on days 12-20, and 7/34 (21%)

- 375 on days 18-27 (57).
- 376

377 One data set (58) measured RSV concentrations in 138 samples of mucus from 31

378 mechanically ventilated infants (Table 3) in a cross sectional study. Concentrations

reporting units, which is assumed to mean virus. Summary statistics were calculated

- 381 from data extracted using WebPlotDigitizer (12).
- 382
- 383 Table 3. Measured concentrations of RSV in mucus.

Data Format	Concentration	Units	Author
Median (25 th , 75 th percentile)	6.5 x 10 ⁸ (1.3 x 10 ⁸ , 5.4 x 10 ⁹)	particles/mL	Van de Pol et al. 2010 (58)

384

Figure 7 shows the weighted average positivity rate for each excretion in subjects with confirmed RSV infections, as calculated from the 26 cross-sectional positivity rate data sets. A breakdown of RSV A versus RSV B positivity rates is shown in Supporting Information Figure S3. While the weighted averages for mucus, saliva, and sputum are all >75%, the weighted average for stool is 14% and there were no urine samples positive for RSV. A chi-square test resulted in a p-value of less than 0.001, rejecting the null hypothesis that positivity rates are the same across excretions.





393

Figure 7. Weighted Average Percentage of Positive RSV Detections in Various
Excretions from Subjects with Confirmed Infection. The reported value for n is the
number of samples included in the metaanalysis for each excretion type. The number
on top of each bar is the percent of samples positive.

398

Because RSV was not detected in urine in any subject, we examined data sets that assayed for RSV in the urine of subjects with respiratory or gastrointestinal symptoms.

- No identified study tested for the presence of RSV in urine. See Supporting Information
- 402 Table S4 for a list of these data sets.
- 403

Metapneumovirus. We identified 15 studies (15,20,24–32,34,46,57,59) containing 20
data sets with information on the shedding of metapneumovirus in excretions of
subjects with confirmed metapneumovirus infections. One data set reported longitudinal
positivity rates, while the remaining 19 reported positivity rate data from cross-sectional
studies with between one (20,29,46) and 156 (26) subjects. All 20 data sets measured
the virus using RT-PCR-based methods.

410

411 The longitudinal data set reported the positivity rates of metapneumovirus detection in

- 412 mucus of seven subjects over 24 days, with 7/7 (100%) testing positive on day 0 since
- 413 diagnosis with metapneumovirus via nasopharyngeal aspirate sample, 3/7 (43%)
- positive on days 4-10, 0/7 positive on days 12-17, and 0/6 positive on days 20-24 (57).
- 415
- 416 Figure 8 shows the weighted average metapneumovirus positivity rates in various
- 417 excretions from the 19 cross-sectional data sets of subjects with confirmed
- 418 metapneumovirus infection. Mucus and sputum have the highest weighted averages at
- 419 >80%, and stool and urine have the lowest (0%), each being evaluated by only a single
- 420 data set with data from six subjects that did not detect any metapneumovirus. A Fisher's
- 421 exact test resulted in a p-value of less than 0.001, rejecting the null hypothesis that
- 422 positivity rates are the same across excretions.
- 423



424

Figure 8. Weighted Average Percentage of Positive Metapneumovirus Detections in

Various Excretions from Subjects with Confirmed Metapneumovirus Infection. The

reported value for n is the number of samples included in the metaanalysis for each
excretion type. The number on top of each bar is the percent of samples positive.

429

430 Since metapneumovirus was not detected in any stool or urine samples of subjects with

431 confirmed metapneumovirus infections, we examined data sets testing for

432 metapneumovirus in the excretions of subjects with respiratory or gastrointestinal

433 symptoms. Metapneumovirus was detected in the stool of subjects with respiratory

434 symptoms, where it was found in 2/331 (0.6%) stool samples (35). However, no

identified data sets tested urine for metapneumovirus. See Supporting Information

Table S5 for additional information on these data sets.

437

438 Seasonal Coronaviruses. We identified 16 studies (15,17,20,22,23,25–

439 28,30,31,34,46,60–62) containing 43 data sets on the shedding of human coronaviruses

440 229E, HKU1, NL63, and/or OC43 in various excretions. No data sets reported any

441 longitudinal shedding data, and no study reported concentration data. All identified data

sets took the form of positivity rates, reporting cross-sectional data with sample sizes

ranging from one (20,22,28,34,60) to 62 (62) subjects with confirmed seasonal

444 coronavirus infection. Of the 43 data sets, 42 measured the virus using RT-PCR-based

445 methods while one used both cultivation and RT-PCR-based methods (61).

446

447 Figure 9 shows the weighted average positivity rates of seasonal coronaviruses in

various excretions from the 43 cross-sectional data sets of subjects with confirmed

seasonal coronavirus infection. Sputum and saliva both have the highest positivity rates

450 (86% and 75%, respectively) and stool and mucus have the lowest (39% and 25%,
451 respectively). No data sets of positivity rates of seasonal coronaviruses in urine of

451 respectively). No data sets of positivity rates of seasonal coronaviruses in unite of 452 subjects with confirmed seasonal coronavirus infection were identified in this review. A

453 Fisher's exact test resulted in a p-value of less than 0.001, rejecting the null hypothesis

454 that positivity rates are the same across excretions. Supporting Information Figure S4

455 shows the weighted averages separated by seasonal coronavirus type.



456

457 Figure 9. Weighted Averages of Percentage of Positive Seasonal Coronavirus

458 Detections in Various Excretions from Subjects with Confirmed Seasonal Coronavirus

Infection. The reported value for n is the number of samples included in the

- 460 metaanalysis for each excretion type. The number on top of each bar is the percent of
- 461 samples positive.
- 462

Since human coronaviruses were not measured in urine of subjects with confirmed
infections, we examined data sets that tested for seasonal coronaviruses in the
excretions of subjects with respiratory or gastrointestinal symptoms. No identified data
sets measured seasonal coronaviruses in urine. See Supporting Information Table S6
for additional information on these data sets.

468

469 Discussion

470

There are limited data available on the shedding of respiratory viruses in stool, saliva,

- sputum, mucus, and urine. Our systematic review of the literature found that the vast
- 473 majority of data sets characterize positivity rates of respiratory viruses in excretions

474 (195/220), while only a few quantify respiratory virus concentration in excretions in a cross-sectional study design (14/220) and even fewer examine longitudinal shedding 475 476 patterns in excretions (11/220). Additionally, the majority of data sets evaluated 477 respiratory viruses in saliva, sputum, and mucus. There was less data available for 478 respiratory virus detection in stool, as no data sets were available for parainfluenza virus and the one data set that tested for metapneumovirus in stool failed to detect any 479 (although one study examining subjects with respiratory or gastrointestinal symptoms 480 reported positive detections of both parainfluenza virus and metapneumovirus in stool 481 (35)). Data sets on respiratory viruses in urine are even more sparse; with no studies 482 483 examining rhinovirus, parainfluenza virus, and seasonal coronaviruses in urine and limited work examining RSV and metapneumovirus in urine (1 study assayed both RSV 484 and metapneumovirus in urine but failed to detect either virus (57)). Only influenza has 485 486 been detected in the urine of subjects with the respective diagnosed infection. This 487 emphasizes the finding that respiratory viruses have been characterized in different excretions to differing extents, limiting the current knowledge of viral concentrations in 488 stool and urine, the more understudied excretions. 489 490

491 Data availability also differed according to respiratory virus type. There were the most 492 excretion data sets for influenza (n = 75) and the least for metapneumovirus and 493 rhinovirus (n = 20 for each). Table 4 highlights the uneven distribution of data as shown 494 in the number of samples evaluated in each excretion and virus.

495

Across the five different excretions, positivity rates for each virus were highest in mucus,
 followed by sputum and then saliva (summarized in Table 4), and hypothesis testing
 rejected the null hypothesis that positivity rates were the same across excretions. The

499 positivity rate of human coronavirus in mucus is the only exception to this pattern, but

500 data were limited (only four samples of mucus tested for human coronaviruses

501 compared to between 39 and 236 mucus samples tested for the other viruses).

502

503 Table 4. Summary of positivity rates, reported as percentage (number of samples 504 positive/number of total samples), of respiratory viruses in excretions of subjects with 505 confirmed infections. 0 indicates excretions were tested but none were positive for the 506 presence of the virus, while n/a indicates no excretions were tested for the presence of 507 the virus. * indicates the virus was not detected in subjects with confirmed infection but 508 has been detected in the excretion although in patients with symptoms. RV is rhinovirus, 509 PIV is parainfluenza virus, Flu is influenza, RSV is respiratory syncytial virus, HMPV is 510 human metapneumovirus, and HCoV is human seasonal coronavirus.

	RV	PIV	Flu	RSV	HMPV	HCoV
Mucus	92%	96%	98%	96%	86%	25%

	(36/39)	(50/52)	(231/236)	(189/197)	(49/57)	(1/4)
Saliva	67% (130/195)	69% (24/35)	82% (370/453)	78% (77/99)	56% (20/36)	75% (58/77)
Sputum	82% (578/704)	82% (319/389)	86% (330/383)	87% (608/697)	80% (334/419)	86% (385/450)
Stool	6% (1/17)	n/a*	36% (200/559)	14% (5/37)	0%* (0/6)	39% (21/54)
Urine	n/a	n/a	58% (19/33)	0% (0/33)	0% (0/6)	n/a

511

512 There were very few quantitative measurements of respiratory virus concentrations in 513 excretions. The most concentration data were available for influenza for which there 514 were 21 data sets (6 longitudinal and 15 cross-sectional), while no concentrations of 515 parainfluenza virus, metapneumovirus, or seasonal coronaviruses were reported in any 516 excretions. No data sets measured any respiratory virus concentration in urine. 517 Comparing viral concentrations between excretions and between respiratory viruses is 518 challenging because of the diversity of quantification methods used and units reported. 519 Units reported include $TCID_{50}/q$ (culture-based methodology), and genomes/mg. 520 copies/g, and particles/mL (RT-PCR-based methodology). Some studies that reported 521 quantitative-type data on respiratory viruses in excretions were excluded from this 522 review because they quantified viruses using units that were not externally valid (e.g. 523 CT values from real time PCR machines) or failed to report sufficient methods to 524 determine the concentration of the respiratory virus in the excretion (e.g. concentration 525 in copies/mL of viral transport medium). 526

527 This work reveals that there is a significant knowledge gap on respiratory virus concentrations in excretions. This information is needed to link concentrations of 528 529 respiratory viruses in wastewater to the number of people infected with the virus in the 530 population contributing to wastewater. We recommend that future studies should 531 explicitly characterize concentrations of respiratory viruses in mucus, saliva, sputum, 532 stool, and urine, reporting standard units (e.g. copies per unit volume of excretion) and 533 complete methods including details established by the Minimum Information for 534 Publication of Quantitative Real-Time PCR Experiments (MIQE) (63) and Environmental Microbiology Minimum Information (EMMI) Guidelines (64). Data are needed across all 535 536 respiratory virus and excretion types to build more robust data sets, but are especially 537 needed for parainfluenza virus, metapneumovirus, and human coronavirus where there 538 was no concentration data identified in this review. While positivity rate data sets are 539 useful in estimating the proportion of infected people that shed a certain respiratory

540 virus in excretions, they cannot provide quantitative estimates of viral shedding necessary to begin to translate wastewater concentrations to individual case numbers in 541 542 a community. Additionally, longitudinal studies that examine the concentrations of respiratory viruses in excretions over time are critical in providing information on both 543 544 the duration of shedding and how concentrations of viruses in excretions vary over time. Such data, for example, are needed to use wastewater data to predict effective 545 reproductive numbers of pathogens (65). Very few studies identified in this review 546 reported longitudinal data and only one study on influenza reported longitudinal 547 concentration data. Additional factors to consider in predicting effective reproductive 548 549 numbers of pathogens through wastewater include the relative contribution of each 550 excretion to wastewater, the design of the sewer system, the wastewater sampling location, and the sample matrix, among others (65). Public health officials and modelers 551 552 interested in applying these results to quantitatively link their wastewater concentrations 553 to numbers of infected individuals should be aware of these limitations and data gaps. 554

555 There are several limitations to this review. We only included studies written in English, 556 which could have excluded studies with relevant data. We did not perform any formal 557 evaluations of bias across the included studies. Additionally, we chose to focus on data sets with measurements made in direct excretions, excluding samples from areas of the 558 body that generate excretions (e.g. swabs and lavages). This narrowed the body of 559 literature applicable to this review. We also focused on positivity rates in the excretions 560 of subjects with confirmed infections, rather than subjects whose infection status was 561 562 unknown, again narrowing the applicable body of literature. This decision was made because positivity rates from subjects whose infection status is unknown are not useful 563 in determining the shedding rates of viruses in excretions: rather the only information 564 relevant to this review that they can provide is evidence that respiratory viruses can be 565 566 shed in certain excretions. Some cross-sectional data sets inadvertently sampled from the same subject multiple times, which could impact the positivity rate data. The chosen 567 statistical tests we performed (chi-square test and Fisher's exact test) do not account for 568 correlation, but some of our data was correlated. However, we could not account for this 569 570 correlation when comparing the data across all excretion types. Finally, we were unable 571 to perform a formal meta-analysis on concentration data given the limited data and 572 inconsistent units reported in the concentration data. As such, we could not examine 573 whether shedding patterns were different across different viral subtypes (for example, 574 RSV A versus RSV B).

575

576 Author Contributions

577 S.L. Conceptualization, Data Curation, Formal analysis, Investigation, Methodology,

- 578 Visualizations, Writing Original Draft Preparation, Writing Review & Editing. A.B.B.
- 579 Conceptualization, Funding Acquisition, Methodology, Project Administration,

580 Resources, Supervision, Validation, Writing – Original Draft Preparation, Writing –

- 581 Review & Editing. M.K.W. Conceptualization, Writing Review & Editing, Methodology.
- 582
- 583 References
- 584
- Pneumonia in children [Internet]. [cited 2022 Dec 22]. Available from:
 https://www.who.int/news-room/fact-sheets/detail/pneumonia
- Moriyama M, Hugentobler WJ, Iwasaki A. Seasonality of Respiratory Viral Infections. Annu Rev Virol. 2020 Sep 29;7(1):83–101.
- van Doorn HR, Yu H. 33 Viral Respiratory Infections. In: Ryan ET, Hill DR, Solomon T,
 Aronson NE, Endy TP, editors. Hunter's Tropical Medicine and Emerging Infectious
 Diseases (Tenth Edition) [Internet]. London: Elsevier; 2020 [cited 2022 Dec 1]. p. 284–8.
 Available from: https://www.sciencedirect.com/science/article/pii/B9780323555128000338
- Hughes B, Duong D, White BJ, Wigginton KR, Chan EMG, Wolfe MK, et al. Respiratory Syncytial Virus (RSV) RNA in Wastewater Settled Solids Reflects RSV Clinical Positivity Rates. Environ Sci Technol Lett. 2022 Feb 8;9(2):173–8.
- 596 5. Wolfe MK, Duong D, Bakker KM, Ammerman M, Mortenson L, Hughes B, et al. Wastewater597 Based Detection of Two Influenza Outbreaks. Environ Sci Technol Lett. 2022 Aug
 598 9;9(8):687–92.
- Brinkman NE, Fout GS, Keely SP. Retrospective Surveillance of Wastewater To Examine
 Seasonal Dynamics of Enterovirus Infections. mSphere. 2017 Jun 14;2(3):e00099-17.
- 601 7. Boehm AB, Hughes B, Doung D, Chan-Herur V, Buchman A, Wolfe MK, et al. Wastewater 602 surveillance of human influenza, metapneumovirus, parainfluenza, respiratory syncytial 603 virus (RSV), rhinovirus, and seasonal coronaviruses during the COVID-19 pandemic 604 [Internet]. medRxiv; 2022 [cited 2022 Dec 22]. p. 2022.09.22.22280218. Available from: 605 https://www.medrxiv.org/content/10.1101/2022.09.22.22280218v1
- 8. Soller J, Jennings W, Schoen M, Boehm A, Wigginton K, Gonzalez R, et al. Modeling
 infection from SARS-CoV-2 wastewater concentrations: promise, limitations, and future
 directions. J Water Health. 2022 Jul 11;20(8):1197–211.
- Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews
 and meta-analyses: the PRISMA statement. BMJ. 2009 Jul 21;339:b2535.
- 611 10. Lowry, S., & Boehm, A. Systematic review of shedding of respiratory viruses in excretions
 612 that comprise wastewater. 2022 Oct 13; Available from:
 613 https://doi.org/10.17605/OSF.IO/ESVYC
- 614 11. Covidence systematic review software [Internet]. Melbourne, Australia: Veritas Health
 615 Innovation; 2022. Available from: www.covidence.org
- 616 12. Rohatgi A. WebPlotDigitizer [Internet]. Pacifica, California, USA; 2021. Available from:
 617 https://automeris.io/WebPlotDigitizer
- 618 13. R Core Team. R: A language and environment for statistical computing. [Internet]. Vienna,
 619 Austria: R Foundation for Statistical Computing; 2021. Available from: https://www.R620 project.org/
- 14. Bergallo M, Dapra V, Rassu M, Calvi C, Galliano I, Montanari P. Prevalence of human
 Rhinovirus in stool samples of children with acute gastroenteritis in Italy. MINERVA
 Biotecnol. 2019;31(1):45–8.
- Branche AR, Walsh ÉE, Formica MA, Falsey AR. Detection of respiratory viruses in sputum
 from adults by use of Automated Multiplex PCR. J Clin Microbiol. 2014;52(10):3590–6.
- 16. Cate TR, Douglas RG Jr, Johnson KM, Couch RB, Knight V. Studies on the Inability of
 Rhinovirus to Survive and Replicate in The Intestinal Tract of Volunteers. Proc Soc Exp Biol
 Med. 1967;124(4):1290–5.

- 17. De Koff EM, Euser SM, Badoux P, Sluiter-Post J, Eggink D, Sanders EAM, et al.
 Respiratory Pathogen Detection in Children: Saliva as a Diagnostic Specimen. Pediatr Infect
 Dis J. 2021;40(9):E351–3.
- 632 18. Gwaltney JM Jr, Moskalski PB, Hendley JO. Hand-to-hand transmission of rhinovirus colds.
 633 Ann Intern Med. 1978;88(4):463–7.
- Heikkinen T, Marttila J, Salmi AA, Ruuskanen O. Nasal Swab versus Nasopharyngeal
 Aspirate for Isolation of Respiratory Viruses. J Clin Microbiol. 2002 Nov;40(11):4337–9.
- 636 20. Huijskens EG, Rossen JW, Kluytmans JA, van der Zanden AG, Koopmans M. Evaluation of
 637 yield of currently available diagnostics by sample type to optimize detection of respiratory
 638 pathogens in patients with a community-acquired pneumonia. Influenza Respir Viruses.
 639 2014;8(2):243–9.
- 21. Jartti T, Lehtinen P, Vuorinen T, Koskenvuo M, Ruuskanen O. Persistence of rhinovirus and
 enterovirus RNA after acute respiratory illness in children. J Med Virol. 2004;72(4):695–9.
- 42 22. Jeong J, Kim K, Jeong S, Park J, Lee S, Seo Y. Comparison of Sputum and
 Nasopharyngeal Swabs for Detection of Respiratory Viruses. J Med Virol.
 2014;86(12):2122–7.
- 645 23. Kim Y, Yun S, Kim M, Park K, Cho C, Yoon S, et al. Comparison between Saliva and
 646 Nasopharyngeal Swab Specimens for Detection of Respiratory Viruses by Multiplex
 647 Reverse Transcription-PCR. J Clin Microbiol. 2017;55(1):226–33.
- 24. Lahti E, Peltola V, Waris M, Virkki R, Rantakokko-Jalava K, Jalava J, et al. Induced sputum
 in the diagnosis of childhood community-acquired pneumonia. THORAX. 2009;64(3):252–7.
- 650 25. Mermond S, Zurawski V, D'Ortenzio E, Driscoll A, DeLuca A, Deloria-Knoll M, et al. Lower
 651 Respiratory Infections Among Hospitalized Children in New Caledonia: A Pilot Study for the
 652 Pneumonia Etiology Research for Child Health Project. Clin Infect Dis. 2012;54:S180–9.
- 26. Thea DM, Seidenberg P, Park DE, Mwananyanda L, Fu W, Shi Q, et al. Limited utility of
 polymerase chain reaction in induced sputum specimens for determining the causes of
 childhood pneumonia in resource-poor settings: Findings from the pneumonia etiology
 research for child health (PERCH) study. Clin Infect Dis. 2017;64:S289–300.
- 27. Wang L, Yang S, Yan X, Liu T, Feng Z, Li G. Comparing the yield of oropharyngeal swabs
 and sputum for detection of 11 common pathogens in hospitalized children with lower
 respiratory tract infection. Virol J. 2019;16.
- 28. Yasuda I, Suzuki M, Maeda H, Terada M, Sando E, Ng C, et al. Respiratory virus detection
 in the upper respiratory tract of asymptomatic, community-dwelling older people. BMC Infect
 Dis. 2022;22(1).
- 29. Yoshii Y, Shimizu K, Morozumi M, Chiba N, Ubukata K, Uruga H, et al. Identification of
 pathogens by comprehensive real-time PCR versus conventional methods in communityacquired pneumonia in Japanese adults. Infect Dis. 2016;48(11–12):782–8.
- 30. Zar HJ, Barnett W, Stadler A, Gardner-Lubbe S, Myer L, Nicol MP. Aetiology of childhood
 pneumonia in a well vaccinated South African birth cohort: a nested case-control study of
 the Drakenstein Child Health Study. Lancet Respir Med. 2016;4(6):463–72.
- 31. Falsey AR, Formica MA, Walsha EE. Yield of sputum for viral detection by reverse transcriptase PCR in adults hospitalized with respiratory illness. J Clin Microbiol. 2012;50(1):21–4.
- 32. Lambert SB, Whiley DM, O'Neill NT, Andrews EC, Canavan FM, Bletchly C, et al.
 Comparing nose-throat swabs and nasopharyngeal aspirates collected from children with
 symptoms for respiratory virus identification using real-time polymerase chain reaction.
 Pediatrics. 2008;122(3):e615-20.
- 33. Robinson J, Lee B, Kothapalli S, Craig W, Fox J. Use of throat swab or saliva specimens for
 detection of respiratory viruses in children. Clin Infect Dis. 2008;46(7):E61–4.
- 34. To KK, Lu L, Yip CC, Poon RW, Fung AM, Cheng A, et al. Additional molecular testing of
 saliva specimens improves the detection of respiratory viruses. Emerg Microbes Infect

[Internet]. 2017;6(6). Available from: https://www.scopus.com/inward/record.uri?eid=2-s2.0 85020311558&doi=10.1038%2femi.2017.35&partnerID=40&md5=a8b831837ea5a3121a9d
 5d9e9dccdf44

- 35. Minodier L, Masse S, Capai L, Blanchon T, Ceccaldi P, van der Werf S, et al. Clinical and
 virological factors associated with gastrointestinal symptoms in patients with acute
 respiratory infection: a two-year prospective study in general practice medicine. BMC Infect
 Dis. 2017;17.
- 36. Al Khatib H, Mathew S, Smatti M, Eltai N, Pathan S, Al Thani A, et al. Profiling of Intestinal
 Microbiota in Patients Infected with Respiratory Influenza A and B Viruses. PATHOGENS.
 2021;10(6).
- 37. Al Khatib H, Coyle P, Al Maslamani M, Al Thani A, Pathan S, Yassine H. Molecular and
 biological characterization of influenza A viruses isolated from human fecal samples. Infect
 Genet Evol. 2021;93.
- 38. Arena C, Amoros J, Vaillant V, Balay K, Chikhi-Brachet R, Varesi L, et al. Simultaneous
 investigation of influenza and enteric viruses in the stools of adult patients consulting in
 general practice for acute diarrhea. Virol J. 2012;9.
- 696 39. Bilder L, Machtei E, Shenhar Y, Kra-Oz Z, Basis F. Salivary Detection of H1N1 Virus: A
 697 Clinical Feasibility Investigation. J Dent Res. 2011;90(9):1136–9.
- 40. Chan M, Lee N, Chan P, Leung T, Sung J. Fecal detection of influenza A virus in patients
 with concurrent respiratory and gastrointestinal symptoms. J Clin Virol. 2009;45(3):208–11.
- 41. Chan M, Lee N, Chan P, To K, Wong R, Ho W, et al. Seasonal Influenza A Virus in Feces of
 Hospitalized Adults. Emerg Infect Dis. 2011;17(11):2038–42.
- 42. Dilantika C, Sedyaningsih E, Kasper M, Agtini M, Listiyaningsih E, Uyeki T, et al. Influenza
 virus infection among pediatric patients reporting diarrhea and influenza-like illness. BMC
 Infect Dis. 2010;10.
- 43. Galar A, Catalan P, Vesperinas L, Miguens I, Munoz I, Garcia-Espona A, et al. Use of Saliva
 Swab for Detection of Influenza Virus in Patients Admitted to an Emergency Department.
 Microbiol Spectr. 2021;9(1).
- 44. Hirose R, Daidoji T, Naito Y, Watanabe Y, Arai Y, Oda T, et al. Long-term detection of
 seasonal influenza RNA in faeces and intestine. Clin Microbiol Infect. 2016;22(9).
- 45. Ho Y, Yoshino A, Tonacio A, Latif A, Caiaffa H, dos Santos S. Detection of pandemic
 influenza-A(H1N1)-2009 virus in urine. INTENSIVE CARE Med. 2013;39(6):1168–9.
- 46. She RC, Taggart EW, Ruegner R, Hymas WC, Bender JM, Weir P, et al. Identifying
 respiratory viruses in nasal mucus from children. Pediatr Infect J. 2010;29(10):970–2.
- 47. Sueki A, Matsuda K, Yamaguchi A, Uehara M, Sugano M, Uehara T, et al. Evaluation of
 saliva as diagnostic materials for influenza virus infection by PCR-based assays. Clin Chim
 Acta. 2016;453:71–4.
- 48. Suryaprasad A, Morgan O, Peebles P, Warner A, Kerin T, Esona M, et al. Virus Detection
 and Duration of Illness Among Patients With 2009 Pandemic Influenza A (H1N1) Virus
 Infection in Texas. Clin Infect Dis. 2011;52:S109–15.
- 49. Tamura D, Fujino M, Ozawa M, Iwatsuki-Horimoto K, Goto H, Sakai-Tagawa Y, et al.
 Significance of seasonal influenza viruses in the stool of pediatric patients. Pediatr Infect Dis J. 2010;29(6):578–9.
- 50. To K, Chan K, Li I, Tsang T, Tse H, Chan J, et al. Viral Load in Patients Infected With
 Pandemic H1N1 2009 Influenza A Virus. J Med Virol. 2010;82(1):1–7.
- 51. To K, Yip C, Lai C, Wong C, Ho D, Pang P, et al. Saliva as a diagnostic specimen for testing
 respiratory virus by a point-of-care molecular assay: a diagnostic validity study. Clin
 Microbiol Infect. 2019;25(3):372–8.
- 52. Wootton SH, Aguilera EA, Wanger A, Jewell A, Patel K, Murphy JR, et al. Detection of
 NH1N1 influenza virus in nonrespiratory sites among children. Pediatr Infect Dis J.
 2014;33(1):95–6.

- 53. Yoo S, Moon S, Kuak E, Yoo H, Kim C, Chey M, et al. Frequent Detection of Pandemic
 (H1N1) 2009 Virus in Stools of Hospitalized Patients. J Clin Microbiol. 2010;48(6):2314–5.
- 54. Yoon J, Yun S, Nam J, Choi S, Lim C. The use of saliva specimens for detection of
 influenza A and B viruses by rapid influenza diagnostic tests. J Virol METHODS.
 2017;243:15–9.
- 55. Yu L, Wang Z, Chen Y, Ding W, Jia H, Chan J, et al. Clinical, Virological, and
 Histopathological Manifestations of Fatal Human Infections by Avian Influenza A(H7N9)
 Virus. Clin Infect Dis. 2013;57(10):1449–57.
- 56. Zhu Z, Liu Y, Xu L, Guan W, Zhang X, Qi T, et al. Extra-pulmonary viral shedding in H7N9
 Avian Influenza patients. J Clin Virol. 2015;69:30–2.
- 57. von Linstow M, Eugen-Olsen J, Koch A, Winther T, Westh H, Hogh B. Excretion patterns of
 human metapneumovirus and respiratory syncytial virus among young children. Eur J Med
 Res. 2006;11(8):329–35.
- 58. de Pol A, Wolfs T, van Loon A, Tacke C, Viveen M, Jansen N, et al. Molecular
 Quantification of Respiratory Syncytial Virus in Respiratory Samples: Reliable Detection
 during the Initial Phase of Infection. J Clin Microbiol. 2010;48(10):3569–74.
- 59. Yajima T, Takahashi H, Kimura N, Sato K, Jingu D, Ubukata S, et al. Comparison of sputum
 specimens and nasopharyngeal swab specimens for diagnosis of acute human
 metapneumovirus-related lower respiratory tract infections in adults. J Clin Virol.
 2022;154:105238.
- Paloniemi M, Lappalainen S, Vesikari T. Commonly circulating human coronaviruses do not
 have a significant role in the etiology of gastrointestinal infections in hospitalized children. J
 Clin Virol. 2015;62:114–7.
- 754 61. Vabret A, Dina J, Gouarin S, Petitjean J, Corbet S, Freymuth F. Detection of the new human
 755 coronavirus HKU1: A report of 6 cases. Clin Infect Dis. 2006;42(5):634–9.
- 756 62. Zhang Y, Su L, Chen Y, Yu S, Zhang D, Mao H, et al. Etiology and clinical characteristics of
 757 SARS-CoV-2 and other human coronaviruses among children in Zhejiang Province, China
 2017-2019. Virol J. 2021;18(1).
- 63. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE
 Guidelines: Minimum Information for Publication of Quantitative Real-Time PCR
 Experiments. Clin Chem. 2009 Apr 1;55(4):611–22.
- 64. Borchardt MA, Boehm AB, Salit M, Spencer SK, Wigginton KR, Noble RT. The
 Environmental Microbiology Minimum Information (EMMI) Guidelines: qPCR and dPCR
 Quality and Reporting for Environmental Microbiology. Environ Sci Technol. 2021 Aug
 3;55(15):10210–23.
- 65. Huisman JS, Scire J, Caduff L, Fernandez -Cassi Xavier, Ganesanandamoorthy P, Kull A,
 et al. Wastewater-Based Estimation of the Effective Reproductive Number of SARS-CoV-2.
 Environ Health Perspect. 130(5):057011.
- 769
- 770
- 771
- 772
- 773
- 774